Migraine Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 65 years old
• People diagnosed with migraine without aura, migraine with aura, or chronic migraine, based on the standard international headache diagnostic guidelines (ICHD-3)
• People whose migraines first started before the age of 50
• People who had at least 4 migraine days per month across each of the three months before the screening period
• People who had at least 4 migraine days during the one-month baseline period before treatment begins
• People who are able to tell the difference between their migraine headaches and other types of headaches (such as tension headaches)
• People willing to follow the treatment schedule using the repetitive transcranial magnetic stimulation (rTMS) device and keep a migraine diary
• People whose migraine medications (including any rescue medications) have not changed in the three months before the study starts — or six months for certain newer migraine prevention injections (Erenumab, Fremanezumab, or Galcanezumab)
• People who agree to keep their medication use completely unchanged for the entire duration of the study
• People using a single migraine prevention medication at a stable dose for at least three months before the study, who can maintain that same dose throughout the study
• People who have not been using other brain stimulation treatments
• People who have not made any changes to acupuncture, relaxation training, biofeedback, or psychological/behavioural therapies in the three months before the study and agree not to change these during the study
• People who are able to read and understand written study materials (such as the patient information sheet, migraine diary, and forms for recording side effects)
• People who completed their baseline headache diary with no more than 5 days of missing entries out of 28 days
• People willing to sign and date a consent form and commit to attending all study visits for the full duration of the study

Who may not be able to join:

• People who had more than 26 headache days in any single month during the three months before the screening visit
• People who had more than 26 headache days during the baseline period
• People who are pregnant
• People currently using Onabotulinumtoxin A (Botox) to manage chronic migraines
• People whose headache condition meets the ICHD-3 definition of medication overuse (confirm with trial site)
• People who have metal objects or implanted devices located above the neckline that could be affected by magnetic fields, including: stents, implanted stimulators, brain or vagus nerve implants (including deep brain stimulators), implanted electrical devices, cochlear implants, magnetic implants, or bullet or grenade fragments
• People who have a heart pacemaker, defibrillator, intracardiac lines, or implanted medication pumps
• People who have previously had a severe reaction to rTMS treatment
• People diagnosed with bipolar disorder, a substance use disorder, or psychosis
• People with a personal or family history of seizures
• People experiencing ongoing chronic sleep deprivation
• People with structural brain conditions such as a brain tumour, stroke, or traumatic brain injury
• People with chronic tinnitus, in the judgement of the trial investigator
• People with other conditions that the trial investigator considers would interfere with the study
• People currently participating in another clinical trial involving an investigational drug or treatment
• People who have had botulinum toxin (Botox) injections for cosmetic purposes on the forehead within six months before joining the study, or who plan to have these during the study
• People with other significant ongoing pain conditions
• People with depression or anxiety scores at or above certain thresholds on standard questionnaires (BDI-II score of 20 or above, or DASS-21 score of 14 or above), as assessed by the trial investigator
• People with serious health conditions considered high risk by the trial investigator, including a history of most cancers within the past five years (excluding certain localised skin cancers or cervical cancer in situ)

Important: Always verify eligibility with the trial site directly before applying.